Dexlansoprazole MR for the management of gastroesophageal reflux disease.

Abstract

Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease. Dexlansoprazole MR has a unique dual delayed-release delivery system that was designed to address unmet needs that may accompany the use of single-release proton pump inhibitors (PPIs), specifically, their short plasma half-life and requirement for meal-associated dosing. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum and the second in the more distal small intestine. This extends plasma concentration and pharmacodynamic effects of dexlansoprazole MR beyond those of single-release PPIs and allows for dosing at any time of the day without regard to meals. This added convenience, along with excellent healing of esophagitis and symptom relief, substantiate its use in patients with gastroesophageal reflux disease requiring PPI treatment.

• Authors: Brian W Behm, David A Peura
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 5 Issue 4 Pg. 439-45 (Aug 2011) ISSN: 1747-4132 [Electronic] England
• PMID: 21780890 (Publication Type: Journal Article, Review)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Delayed-Action Preparations
• Lansoprazole
• Dexlansoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Anti-Ulcer Agents (adverse effects, pharmacokinetics, therapeutic use)
• Delayed-Action Preparations (adverse effects, pharmacokinetics, therapeutic use)
• Dexlansoprazole
• Esophagitis (drug therapy)
• Gastroesophageal Reflux (drug therapy)
• Humans
• Lansoprazole
• Treatment Outcome
• United States